ATX-Gx™ for your Next
Antibody Discovery Campaign
at MImAbs

MImAbs Gets Certification from Alloy Therapeutics to Access ATX-GX™ Humanized Mice Platform for its Antibody Generation Services.

Join the fastest growing in vivo human antibody discovery platform

• ATX-Gx™ is currently used by a rapidly growing community of discovery groups
  across Fortune 50 biopharma, small and medium biotech companies, and
  academic research labs

• MImAbs is an Alloy Certified Service Provider who can support licensees of the
  ATX-Gx™ platform on their discovery projects

Best-in-class immunocompetence across a suite of transgenic mice

• ATX-Gx™ platform is a suite of transgenic mice collectively engineered to drive the greatest potential diversity and broadest epitopic coverage of unique human antibodies binding to your target of interest
• The core transgenic platform was developed over the last 12 years—first inside a
  Fortune 10 biopharma and later at Alloy—with rigorous attention to animal health,
  immunocompetence, and freedom to operate

Groundbreaking business terms with access in as little as two weeks

• World’s first royalty-free humanized mouse discovery platform

• Simple licensing process, ability to start working with ATX-Gx™ mice in as little as
  two weeks
• Permitted to design your own KO and bespoke genetic modifications for ATX-Gx™

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific
community to make better medicines together. Through a community of partners, Alloy democratizes
access to tools, technologies, services, and company creation capabilities that are foundational for
discovering and developing therapeutic biologics. The company facilitates affordable, non-exclusive
access to the entire drug discovery community from academic scientists, small and medium biotech,
to the largest biopharma. Alloy’s lead offering, the ATX-Gx™ platform, is a human therapeutic antibody
discovery platform consisting of a growing suite of proprietary transgenic mice strains. Founded in
2017 and privately funded by visionary investors, Alloy is headquartered in Boston, MA with European
labs in Cambridge, UK. As a reflection of Alloy’s relentless commitment to the scientific community,
Alloy reinvests 100% of its revenue in innovation and access to innovation.

ATX-Gx™ Platform

A portfolio of highly immunocompetent strains that together offer (i) full human heavy chain
repertoire, (ii) human kappa and human lambda chain repertoire, (iii) haplotype diversity, and (iv) limited immunodominance.

ATX-GK Case Study